{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-032107","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-10-06T11:45:18+00:00","discovered_at":"2026-10-06T11:50:00.277198+00:00","generated_at":"2026-10-12T16:36:16.670178+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Valion Bio names Thomas Jensen Board Chair; touts $35.6M government funding for Entolimod ARS program","bullets":["Thomas H. Jensen named Board Chair of Valion Bio; he is CEO and a director of Nasdaq-listed Allarity Therapeutics, which he has led since December 2023.","Entolimod is an investigational TLR5 agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS), holding FDA Fast Track and Orphan Drug designations for ARS.","Entolimod development has received approximately $35.6 million in non-dilutive funding from several U.S. government agencies.","Jensen said that to the company's knowledge there is no FDA-approved treatment for gastrointestinal ARS; longer term he sees potential in cancer supportive care.","Jensen is working with Interim CEO Dean Zikria and President/COO/CFO Lisa Wolf; drug supply is controlled through wholly owned U.S.-based CDMO Velocity Bioworks."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-032107","json":"https://secwatch.observer/filing/0001437749-26-032107.json","markdown":"https://secwatch.observer/filing/0001437749-26-032107.md","text":"https://secwatch.observer/filing/0001437749-26-032107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/0001437749-26-032107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/vbio20261005_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:36:16.670178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}